Incubator

The Innovation Gateway incubator is intended for startup or early-stage companies that are involved in the research and development of new products and services.[/lead]

Companies must have established research relationships with University of Georgia researchers, or they must have an interest in initiating those relationships. Priority consideration will be given to those companies who have a technology licensing agreement with the University of Georgia Research Foundation.

Contact

Eberhart, Derek E
Director, Innovation Gateway
Boyd Graduate Studies Research Center (GSRC)
200 D. W. Brooks Drive Rm 0809
Athens, GA 30602-5016
706-542-2207
dereke@uga.edu

Biggs, Ian M
Sr. Associate Director – Startups, Innovation Gateway
Center for Applied Genetic Technologies (CAGT)
111 Riverbend Road Rm 0267
Athens, GA 30602-1514
706-542-4308
> ibiggs@uga.edu

Admissions Criteria

The Innovation Gateway assesses companies’ qualifications for admission based upon the following criteria:

  • Industry Application – Innovation Gateway is interested in companies that reflect the University of Georgia’s research portfolio. Technologies include biotechnology, agribusiness, biofuels, pharmaceutical, therapeutic, diagnostic, medical device, and engineering fields
  • Market Opportunity – There must be a significant multi-million dollar market opportunity generated through products, or a combination of products and services.
  • Financial Status – The company should have already secured an initial round of funding, and be prepared to either pursue additional funding or generate sales revenue.
  • Management Expertise – At least one member of the management team (CEO/COO) must have a track record within the industry application or analogous industry experience.
  • Intellectual Property – A strong intellectual property portfolio anchored by issued and/or pending patents, copyrights, and trade secrets is essential to maintaining a competitive advantage in highly technical fields such as biotechnology and engineering.
  • Relationship to the University – University relationships can be in the form of faculty and/or student founders, IP license/option/research agreements, or an interest in using University core facilities.
  • Job Creation – Companies should make a commitment to hiring between 4 and 20 employees in the Athens area within one year of assuming GBBC residency status.

Admissions Process

In order to be considered for admittance to the Innovation Gateway incubator, companies must submit an Executive Summary with cover letter to gateway@uga.edu.

The document should include:

  • a description of technology
  • an assessment of the market opportunity
  • a description of how the company’s technology capitalizes on this opportunity
  • a review of direct and indirect competitors
  • financial projections for the first five years; and
  • a description of the management team’s relevant experience.
  • A full Business Plan may be submitted in support of the Executive Summary.

Innovation Gateway Incubator Policies

Innovation Gateway Companies

These companies meet Innovation Gateway admission criteria: industry application, market opportunity, financial status, management experience, intellectual property, relationship to UGA and job creation.

CompanyCEO or Company RepresentativeDescription
AbeomeRichard ShimketsDeveloping a technology that greatly enhances the speed and efficiency of monoclonal antibody discovery and production.
Argent DiagnosticsAttilio BaldassiCommercializing a diagnostic platform using Surface Enhanced Raman Spectroscopy (SERS) to target bio-molecules. The technology is superior to current PCR methods in sensitivity and speed.
ArunA BiomedicalSteve SticeCommercializing products and services derived from or related to human stem cells.
BioteceraYajun YanBiotecEra is manufacturing specialty chemicals and nutritional supplements such as the anti-depressant, 5-HTP using modern biotechnological techniques.
GlycoscientificRon OrlandoCommercializing reagents for mass spec-based carbohydrate analysis.
Glycosensors & DiagnosticsKausar SamliDeveloping carbohydrate-related technologies using advanced computational simulations.
Meredian Holdings GroupJoe GrubbsCommercializing sustainable, renewable bioplastic technologies for global customers.
Molecular TherapeuticsBran RitchieManufacturing Silvion® and Silvaklenz®, solutions proven to kill most pathogenic bacteria.
MuniRem (formerly Planteco)Valentine NzengungProvides a range of environmental remediation services and sustainable green technologies.
CyanVacBiao HeA vaccine development company advancing the use of ParaInfluenza 5 (PIV-5) as a vaccine platform for the prevention of both animal and human infectious diseases.
PathensFred QuinnCommercializing discoveries made in the field of vaccination, including a cold-adapted bacterium that can provide a platform technology for the production of a wide range of vaccines or vaccine vectors.
PhotoChemJosh SharpDeveloping an instrument to rapidly compare the 3-dimensional structure of proteins.
PhytoSynthetixIvan KruglakDesigns high-performance lighting systems for optimal plant growth.
rPeptide: Recombinant Peptide Technologies, LLCNeelam DattaProvides a range of research products and services, with a focus on products for Alzheimer's and Parkinson's research. Their beta amyloids, synucleins and taus are produced recombinantly, ensuring a high degree of batch-to-batch reproducibility.
SwissaustralFelipe SarmientoProduces novel enzymes derived from extremophilic microorganisms that are more stable and effective than alternatives when used in challenging industrial settings.
ViamuneAlex HarveyViaMune is a preclinical-stage company with a proprietary immunotherapy platform that enables precise targeting of tumor associated glycopeptides.
ViCapsysSuren ChavanDeveloping a cure for insulin dependent diabetes. ViCapsys' lead clinical candidate has demonstrated efficacy mitigating immune response and foreign body recognition, rendering encapsulated islet transplantation a viable solution.
Vitamin DerivativesHardy EdwardsManufactures 1-OH-Vitamin D3 for the global poultry industry. This particular D3 derivative is the most bioactive on the market, preventing fibial dyschoncroplasia.

Although affiliate companies do not meet residency criteria, they have a substantive relationship to UGA through intellectual property, sponsored research, and faculty participation.

CompanyCEODescription
ARChemTom StriblingCommercializing software that provides a rapid and accurate physicochemical property calculator to the chemical and pharmaceutical market.
MerialCarsten HellmannCommercializing animal pharmaceutical products, vaccines and services for health and well-being of companion animals (dogs, cats and horses), production animals (cattle, poultry, swine), and wildlife. Global operations include facilities located at UGA, which develop collaborative opportunities with UGA scientists.
Millennium CryogenicsPaul MontelloProvides low-temperature backup and archiving services to academic, corporate and government research laboratories.
NueMDMassoud AlibakhshProvides health IT tools for the efficient management of physician practices.
Proventus BioStephen BellProventus Bio is a recently formed biotechnology company focused on enhancing bioproduction through genetic engineering of vaccine and biotherapeutic cell lines.
ViacyteAllan RobinsA regenerative medicine company commercializing cell therapies to treat diabetes. Headquartered in San Diego.
WeRecycleJenna JambeckProvides a platform to facilitate communication about waste between citizens and their community through a community-built map of outdoor and event trash cans and recycle bins and a mobile app.

Companies are eligible for graduation from Innovation Gateway when established revenue, financing, management, facilities or production milestones are achieved.

CompanyCEODescription
AlgixMike Van DrunenDeveloping algal bioplastics using a protein-based thermomechanical approach. These protein based bioplastics exhibit superior biodegradability to existing bioplastics.
ApgenDavid GlassApplied PhytoGenetics, Inc. utilizes plants, trees and grasses to remove or degrade hazardous materials from the environment through phytoremediation.
Bacterial BarcodesAcquired by BioMérieux (2006)Commercializes DiversiLab, a patented system of automated microbial genotyping offering solutions to track hospital-acquired infections.
BioInquireAquired by NuSep (2010)Develops software solutions for proteomic data-mining applications.
Body Surface TranslationsGregg BeVierDeveloping a handheld device capable of remotely and accurately assessing the weight of an animal. Currently marketed to pork producers.
IS3DTom RobertsonDevelops inquiry-based 3-D educational materials that increase high school student performance and interest in science and technology.
P3 LaboratoriesJeffrey H. PingProvides consulting, development, production, and post-marketing technical support to the pharmaceutical industry for the development of niche products.
Synageva BiopharmaDiscovers, develops and delivers medicines for patients with rare disease and high unmet medical need.
ViaGenAcquired by ProLinia (2003)Identifies economically important genetic traits in any animal species and applies them to commercial breeding operations.